Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) Income towards Parent Company: 2020-2023

Historic Income towards Parent Company for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to -$15.5 million.

  • Immuneering's Income towards Parent Company fell 15.44% to -$15.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$54.8 million, marking a year-over-year decrease of 8.03%. This contributed to the annual value of -$54.8 million for FY2023, which is 8.50% down from last year.
  • Latest data reveals that Immuneering reported Income towards Parent Company of -$15.5 million as of Q4 2023, which was down 18.95% from -$13.1 million recorded in Q3 2023.
  • Immuneering's 5-year Income towards Parent Company high stood at -$3.2 million for Q2 2020, and its period low was -$15.5 million during Q4 2023.
  • Over the past 3 years, Immuneering's median Income towards Parent Company value was -$12.6 million (recorded in 2022), while the average stood at -$11.6 million.
  • Data for Immuneering's Income towards Parent Company shows a maximum YoY crashed of 149.56% (in 2021) over the last 5 years.
  • Quarterly analysis of 4 years shows Immuneering's Income towards Parent Company stood at -$5.8 million in 2020, then slumped by 88.02% to -$11.0 million in 2021, then declined by 22.75% to -$13.5 million in 2022, then declined by 15.44% to -$15.5 million in 2023.
  • Its Income towards Parent Company stands at -$15.5 million for Q4 2023, versus -$13.1 million for Q3 2023 and -$12.3 million for Q2 2023.